DICE Therapeutics, Inc. clinical trials
Acquired by Eli Lilly and Company, Aug 9, 2023 · source ↗
The registry lists 10 studies whose lead sponsor is DICE Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
- 10studies on the registry
- 0open to participants now
Before and after it joined Eli Lilly and Company
- First submitted before DICE Therapeutics, Inc. became part of Eli Lilly and Company
- 1
- First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- 8
- Unclear, or no submission date
- 1
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs DICE Therapeutics, Inc.’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
All 10 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed10100%
Over the years
- 21
- 22
- 23
- 524
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company10 studies
Something wrong with this grouping? Tell us on the Eli Lilly and Company page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Eli Lilly and Company studies →
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy ParticipantsCompletedNCT06092931Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult ParticipantsCompletedNCT05994807Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted the day DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT06602219Phase 2
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- Mass Balance and Pharmacokinetics (PK) of [14C]-DC-806 in Healthy Male ParticipantsCompletedNCT06045000Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study to Assess LY4100511 (DC-853) in Healthy Adult ParticipantsCompletedNCT06345794Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05896527Phase 2
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted before DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian ParticipantsCompletedNCT06311656Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisCompletedNCT06808815Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy ParticipantsCompletedNCT06503679Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company
- A Study of LY4100511 (DC-853) Mass Balance and Absolute Bioavailability of LY4100511 in Healthy Male ParticipantsCompletedNCT06627088Phase 1
Sponsor listed in the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · First submitted after DICE Therapeutics, Inc. became part of Eli Lilly and Company